Filing Details
- Accession Number:
- 0001181431-11-060888
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-12-16 17:05:43
- Reporting Period:
- 2011-11-30
- Filing Date:
- 2011-12-16
- Accepted Time:
- 2011-12-16 17:05:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1361103 | Complete Genomics Inc | GNOM | Services-Commercial Physical & Biological Research (8731) | 203226545 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1250018 | E Andrew Senyei | C/O Enterprise Partners 2223 Avenida De La Playa, Suite 300 La Jolla CA 92037-3218 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.001 | Acquisiton | 2011-11-30 | 1,666 | $0.00 | 1,666 | No | 4 | M | Direct | |
Common Stock, Par Value $0.001 | Acquisiton | 2011-12-14 | 100,000 | $3.05 | 201,043 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2011-11-30 | 1,666 | $0.00 | 1,666 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
3,334 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $0.001 | 2,052,418 | Indirect | See Footnote |
Common Stock, Par Value $0.001 | 667,068 | Indirect | See Footnote |
Footnotes
- The shares were acquired upon vesting and conversion of Restricted Stock Units, which were received as a grant for which no consideration was paid.
- The shares are owned by Enterprise Partners Management, LLC ("Enterprise LLC"). Andrew E. Senyei, M.D. is a managing director of Enterprise LLC and shares voting and investment power over the shares held by Enterprise LLC. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
- The shares are owned by Enterprise Partners VI, LP (Enterprise VI"). Enterprise Management Partners VI, LLC (Enterprise VI LLC") serves as the general partner of Enterprise VI. Andrew E. Senyei, M.D. is a managing director of Enterprise VI LLC and shares voting and investment power over the shares held by Enterprise VI. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
- The shares are owned by Enterprise Partners V, LP ("Enterprise V"). Enterprise Management Partners V, LLC ("Enterprise V LLC") serves as the general partner of Enterprise V. Andrew E. Senyei, M.D. is a managing director of Enterprise V LLC and shares voting and investment power over the shares held by Enterprise V. The Reporting Person disclaims beneficial ownership of the shares reported herein, except to the extent of his proportionate pecuniary interest therein.
- Upon vesting, Reporting Person is entitled to receive one share of common stock for each restricted stock unit.
- The restricted stock units vest in three successive and equal annual installments measured from November 30, 2010, such that the restricted stock units will vest in full on the third anniversary of November 30, 3010, subject to the Reporting Person's continued employment or service relationship with the Issuer on each of the vesting dates. Such restricted stock units include a change of control provision such that all unvested awards will immediately vest and become exercisable in connection with a change of control of Issuer.